合作目標是測試在臨床試驗中的區塊鏈技術是否提供了一個分散的框架，以保證數據完整性、來源、透明度和患者賦權以及過程自動化，最終以降低成本提高試驗質量和患者安全性。
Boehringer Ingelheim Ltd. and IBM Canada announced today at the Healthcare Information and Management Systems Society conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials.
勃林格殷格翰（Boehringer Ingelheim）Ltd .和 IBM Canada 今天在弗洛裡達州奧蘭多召開的醫療信息和管理系統協會會議上宣佈，他們計劃在臨床試驗中探索使用區塊鏈技術。
This collaboration underscores Boehringer Ingelheim's commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada.
這種合作強調了勃林格殷格翰（Boehringer Ingelheim）對醫療創新的承諾，並標誌著區塊鏈技術將首次在加拿大的臨床試驗環境中得到探索。
Based on the findings of regulatory authorities, processes to ensure the quality of clinical trials are frequently inadequate, and clinical trial records are often erroneous or incomplete, which may put patient safety and interpretability of trials at risk.
根據監管部門的調查結果，確保臨床試驗質量的過程經常不充分，臨床試驗記錄往往錯誤或不完整，可能使患者的安全性和試驗的可解釋性受到威脅。
Significant opportunity exists to improve the quality of clinical trial processes and record keeping. Boehringer Ingelheim (Canada) Ltd. and IBM Canada aim to test whether blockchain technology in clinical trials provides a decentralized framework that enables data integrity, provenance, transparency, and patient empowerment as well as automation of processes, ultimately improving trial quality and patient safety at reduced cost.
提高臨床試驗過程質量和記錄保存的重要機會。勃林格殷格翰（Boehringer Ingelheim）（加拿大）有限公司和 IBM 加拿大公司的目標是測試在臨床試驗中的區塊鏈技術是否提供了一個分散的框架，使數據完整性、來源、透明度和患者賦權以及過程自動化，最終以降低成本提高試驗質量和患者安全性。
"Our guiding philosophy is to bring value to patients and the healthcare system through innovation," said Dr. Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. "The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment. Patients are at the heart of everything we do, so we are looking into novel solutions to improve patient safety and empowerment."
勃林格殷格翰（Boehringer Ingelheim）（加拿大）有限公司醫療和監管事務副總裁 Uli Br ö dl 博士說：“我們的指導思想是通過創新為患者和醫療系統帶來價值。臨床試驗生態系統非常複雜，涉及不同的利益相關者，因此信任有限。沒有真正的病人授權，透明度和過程效率低下。病人是我們所做一切的核心，因此我們正在尋找新的解決方案，以改善病人的安全和增強能力。”
IBM Canada brings core blockchain technologies to this collaboration which provides patient consent, secure health data exchange and patient engagement. IBM's technology helps provide trust and transparency around the complex trial process.
IBMCanada 為這種協作提供了核心區塊鏈技術，它提供了患者同意、安全的健康數據交換和患者參與。IBM 的技術有助於在複雜的測試過程中提供信任和透明度。
閱讀更多 匯眾醫療 的文章
